Related Experiment Video
Updated: Jul 5, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
[Velaxin (venlafaxine) in the treatment of anxious depression]
Abstract:
Thirty patients (7 male, 23 female) mean age 35,3+/-7,8 years with anxious or anxious-apathic depression, including 24 in-patients and 6 out-patients. They were treated during 8 weeks with velaxin in dosage 225-375 mg per day. The changes of patient state evaluated with rating scales (CGI, HDRS, BDI, HADS-21). Twenty-seven patients (90%) completely underwent the course of treatment. Responders according to CGI were 25 (83,3%) cases: "improvement" - 16 (59,3%), "apparent improvement" - 9 (33,3%); "minor improvement" - 2 (7,4%) patients. The complete reduction of depressive symptoms was recorded in 33,3% of cases. The safety of velaxin in moderate therapeutic doses as well as improvement of laboratory and instrumental characteristics of somatic state was confirmed.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Electroconvulsive Therapy
Anxiolytic Drugs: Benzodiazepines and Buspirone
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.